Seagen

Seagen, previously Seattle Genetics, Inc. is a biotechnology company that engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. It is a company that is advancing a pipeline of novel therapies for solid tumors and blood-related cancers.

The company rebranded as Seagen in 2020. In September 2020, the company obtained FDA approvals for two cancer drugs and partnered with Merck for a Phase II antibody-drug conjugate and a marketed drug.

The companies product, Adcetris (brentuximab vedotin), received approval in 2011 for Hodgkin’s lymphoma and approved for anaplastic large-cell lymphoma, a type of T-cell non-Hodgkin’s lymphoma. Subsequently, it won approval for its second product, Padcev (enfortumab vedotin-ejfv), for locally advanced or metastatic urothelial cancer, and it received a nod for Tukysa (tucatinib), for HER2-positive breast cancer.